Reinventing Treatment Selection for Better Patient Care
When biomarkers fall short, patients deserve better
Behind every tumor is a person fighting for time and quality of life, yet many cancers still lack reliable biomarkers to guide therapy.
Standard care can help, but without a truly personalized view of tumor biology it often misses what drives response, so better decisions require deeper biological insight.
At BeLiver, we dig deeper into tumor biology to bring the precision every patient deserves, because guessing isn't an option.

Advancing care by supporting oncologists with data-driven personalized decisions
BeLiver is developing a decision support platform designed to estimate each individual's likelihood of benefit across available therapies and turn complex biological and clinical signals into clear, clinician‑ready reports.
By spotlighting options with higher probability of response, it aims to shorten time on ineffective care and support confident, data-driven choices that may improve outcomes and patient experience.
Discover our services
High resolution proteomic profiling coupled with AI : unlocking precision oncology
High resolution proteomic profiling of tumor biopsies captures the tumor's functional state within precision oncology workflows, while advanced machine learning interprets multi-protein signatures to estimate the likelihood of response and support individualized treatment planning.
A dual-impact platform : treating today, discovering tomorrow
Beyond immediate choices, this approach reveals novel protein targets, stratifies patients for future studies and partnerships, and accelerates discovery alongside care.
Discover the science
BeLiver's services are currently under development and are not yet commercially available. They have not received regulatory clearance (CE marking under IVDR in Europe). The information on this website describes our research and development activities and does not constitute a commercial offer or medical advice.
Interested in partnering with us?
Clinicians, researchers, pharma companies, hospitals: join us in building a future where every cancer patient receives the right treatment from the start.
Connect with us











